| Year |
Citation |
Score |
| 2010 |
Mah CS, Falk DJ, Germain SA, Kelley JS, Lewis MA, Cloutier DA, DeRuisseau LR, Conlon TJ, Cresawn KO, Fraites TJ, Campbell-Thompson M, Fuller DD, Byrne BJ. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 502-10. PMID 20104213 DOI: 10.1038/Mt.2009.305 |
0.748 |
|
| 2005 |
Mah C, Cresawn KO, Fraites TJ, Pacak CA, Lewis MA, Zolotukhin I, Byrne BJ. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors Gene Therapy. 12: 1405-1409. PMID 15920463 DOI: 10.1038/Sj.Gt.3302550 |
0.78 |
|
| 2005 |
Cresawn KO, Fraites TJ, Wasserfall C, Atkinson M, Lewis M, Porvasnik S, Liu C, Mah C, Byrne BJ. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid α-glucosidase in a model of glycogen storage disease type II Human Gene Therapy. 16: 68-80. PMID 15703490 DOI: 10.1089/Hum.2005.16.68 |
0.807 |
|
| 2005 |
Cresawn KO, Mah CS, Fraites TJ, Lewis MA, Zolotukhin I, Byrne BJ. 909. Sustained Correction of Glycogen Storage Disease Type II by rAAV1 Vector-Mediated Gene Therapy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.452 |
0.832 |
|
| 2005 |
DeRuisseau LR, Mah CS, Fraites TJ, Fuller DD, Byrne BJ. 818. Recombinant AAV1-Mediated Treatment of CNS Glycogen Accumulation in Mouse Model of Glycogen Storage Disease Type II Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.361 |
0.805 |
|
| 2004 |
Rucker M, Fraites TJ, Porvasnik SL, Lewis MA, Zolotukhin I, Cloutier DA, Byrne BJ. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development (Cambridge, England). 131: 3007-19. PMID 15169761 DOI: 10.1242/Dev.01169 |
0.69 |
|
| 2004 |
Mah C, Fraites TJ, Cresawn KO, Zolotukhin I, Lewis MA, Byrne BJ. A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 458-63. PMID 15006614 DOI: 10.1016/J.Ymthe.2004.01.006 |
0.773 |
|
| 2004 |
Cresawn KO, Wasserfall C, Atkinson MA, Mah C, Fraites TJ, Zolotukhin I, Byrne BJ. 250. Cross-Correction in Pompe Mice after Immunomodulation and Hepatic Delivery of Recombinant AAA5 and AAV8 Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.191 |
0.809 |
|
| 2002 |
Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ, Snyder RO. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (San Diego, Calif.). 28: 158-67. PMID 12413414 DOI: 10.1016/S1046-2023(02)00220-7 |
0.6 |
|
| 2002 |
Mah C, Fraites TJ, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy Molecular Therapy. 6: 106-112. PMID 12095310 DOI: 10.1006/Mthe.2001.0636 |
0.617 |
|
| 2002 |
Fraites TJ, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I, Pauly DF, Raben N, Plotz PH, Powers SK, Kessler PD, Byrne BJ. Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors Molecular Therapy. 5: 571-578. PMID 11991748 DOI: 10.1006/Mthe.2002.0580 |
0.71 |
|
| 2001 |
Pauly DF, Fraites TJ, Toma C, Bayes HS, Huie ML, Hirschhorn R, Plotz PH, Raben N, Kessler PD, Byrne BJ. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Human Gene Therapy. 12: 527-38. PMID 11268285 DOI: 10.1089/104303401300042447 |
0.655 |
|
| Show low-probability matches. |